Baudax Bio, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

Commitments and Contingencies - Additional Information (Details)

Commitments and Contingencies - Additional Information (Details) € in Thousands			1 Months Ended		3 Months Ended			9 Months Ended
	Feb. 01, 2021 USD ($) Milestonepayment	Apr. 10, 2015 USD ($)	Feb. 29, 2020 USD ($) Milestonepayment	Jun. 30, 2017 USD ($)	Mar. 31, 2022 USD ($)	Jun. 30, 2019 USD ($)	Mar. 31, 2019 USD ($)	Sep. 30, 2022 USD ($)	Sep. 30, 2022 EUR (€)
Supply Commitment [Line Items]
Business acquisition, contingent consideration, equal annual milestone payments					$ 1,200,000
Purchase Commitment
Supply Commitment [Line Items]
Purchase commitment non cancelable and cancelable								$ 3,419,000
Cornell University \| Neuromuscular Blocking Agents License Agreement
Supply Commitment [Line Items]
Amount of royalty payments due or payable								0
Alkermes Plc \| Amendment to Purchase and Sale Agreement
Supply Commitment [Line Items]
Collaborative arrangements, milestone payments upon achievement of regulatory and sales milestones								$ 22,629,000
Alkermes Plc \| Amendment to Purchase and Sale Agreement \| Contingent Consideration, Fourth Component
Supply Commitment [Line Items]
Maximum royalty payment percentage								30.00%	30.00%
Alkermes Plc \| Amendment to Purchase and Sale Agreement \| Milestone Payments Due Beginning On First Anniversary Of Regulatory Approval \| Contingent Consideration, Second Component
Supply Commitment [Line Items]
Business acquisition contingent consideration possible milestone payments	$ 45,000,000
Business acquisition, contingent consideration, number of equal annual milestone payments \| Milestonepayment	7
Business acquisition, contingent consideration, equal annual milestone payments	$ 6,400,000
U.S \| Cornell University \| Neuromuscular Blocking Agents License Agreement
Supply Commitment [Line Items]
Regulatory approval and commercialization milestones				$ 5,000,000
European \| Cornell University \| Neuromuscular Blocking Agents License Agreement
Supply Commitment [Line Items]
Regulatory approval and commercialization milestones				3,000,000
Minimum \| Cornell University \| Neuromuscular Blocking Agents License Agreement
Supply Commitment [Line Items]
Cost, Maintenance				70,000
Minimum \| Alkermes Plc \| Amendment to Purchase and Sale Agreement \| Contingent Consideration, Fourth Component
Supply Commitment [Line Items]
Royalty payment percentage								10.00%	10.00%
Maximum \| Executive Officer
Supply Commitment [Line Items]
Aggregate annual base salaries of employment agreement								$ 927,000
Maximum \| Cornell University \| Neuromuscular Blocking Agents License Agreement
Supply Commitment [Line Items]
Cost, Maintenance				$ 125,000
Maximum \| Alkermes Plc \| Amendment to Purchase and Sale Agreement \| Contingent Consideration, Fourth Component
Supply Commitment [Line Items]
Royalty payment percentage								12.00%	12.00%
Recro \| Alkermes Transaction
Supply Commitment [Line Items]
Collaborative arrangements, milestone payments upon achievement of regulatory and sales milestones		$ 140,000,000
Recro \| Alkermes Transaction \| Regulatory Approval and Net Sales Milestones
Supply Commitment [Line Items]
Collaborative arrangements, milestone payments upon achievement of regulatory and sales milestones		$ 60,000,000
Collaborative arrangements, milestone payments period		7 years
Recro \| Alkermes Plc \| Amendment to Purchase and Sale Agreement \| Alkermes Transaction \| Contingent Consideration, First Component
Supply Commitment [Line Items]
Business acquisition contingent consideration, first milestone payment							$ 5,000,000
Business acquisition contingent consideration possible milestone payments						$ 5,000,000
Recro \| Alkermes Plc \| Amendment to Purchase and Sale Agreement \| Alkermes Transaction \| Contingent Consideration, Fourth Component
Supply Commitment [Line Items]
Maximum royalty payment percentage								30.00%	30.00%
Recro \| Alkermes Plc \| Amendment to Purchase and Sale Agreement \| Alkermes Transaction \| Milestone Payments Due, Following Regulatory Approval \| Contingent Consideration, Second Component
Supply Commitment [Line Items]
Business acquisition contingent consideration possible milestone payments			$ 5,000,000
Recro \| Alkermes Plc \| Amendment to Purchase and Sale Agreement \| Alkermes Transaction \| Milestone Payments Due Beginning On First Anniversary Of Regulatory Approval \| Contingent Consideration, Second Component
Supply Commitment [Line Items]
Business acquisition contingent consideration possible milestone payments			$ 45,000,000
Business acquisition, contingent consideration, number of equal annual milestone payments \| Milestonepayment			7
Business acquisition, contingent consideration, equal annual milestone payments			$ 6,400,000
Recro \| Minimum \| Alkermes Plc \| Amendment to Purchase and Sale Agreement \| Alkermes Transaction \| Contingent Consideration, Fourth Component
Supply Commitment [Line Items]
Royalty payment percentage								10.00%	10.00%
Recro \| Maximum \| Alkermes Plc \| Amendment to Purchase and Sale Agreement \| Alkermes Transaction \| Contingent Consideration, Fourth Component
Supply Commitment [Line Items]
Royalty payment percentage								12.00%	12.00%
Recro \| Dexmedetomidine License Agreement
Supply Commitment [Line Items]
Contingent milestone payments, maximum								$ 20,084,000	€ 20,500
Amount of royalty payments due or payable								$ 0
Recro \| Dexmedetomidine License Agreement \| Minimum
Supply Commitment [Line Items]
Percentage of royalty payments								10.00%	10.00%
Recro \| Dexmedetomidine License Agreement \| Maximum
Supply Commitment [Line Items]
Percentage of royalty payments								20.00%	20.00%
Recro \| Fadolmidine License Agreement
Supply Commitment [Line Items]
Amount of royalty payments due or payable								$ 0
Additional contingent milestones payment								$ 11,954,000	€ 12,200
Recro \| Fadolmidine License Agreement \| Minimum
Supply Commitment [Line Items]
Percentage of royalty payments								10.00%	10.00%
Recro \| Fadolmidine License Agreement \| Maximum
Supply Commitment [Line Items]
Percentage of royalty payments								15.00%	15.00%